3839.HK Chia Tai Earnings: $773M Revenue, B+ Grade

Chia Tai Enterprises International Limited (3839.HK) released earnings on May 13, 2026, posting $773.34 million in revenue and $0.1701 earnings per share. The Hong Kong-based pharmaceutical and industrial equipment manufacturer operates through two segments: biochemical products like feed additives and industrial machinery services. With a $2.16 billion market cap, the company serves markets across Mainland China, Asia Pacific, Americas, and Europe. Meyka AI rates 3839.HK with a grade of B+, reflecting mixed fundamentals. The stock declined 4.5% following the announcement, trading at HK$8.69 versus the previous close of HK$9.10.

Earnings Results and Financial Performance

Chia Tai delivered solid operational results despite market headwinds. The company generated $773.34 million in revenue for the reporting period, demonstrating continued demand across its diversified business segments.

Revenue Generation

The $773.34 million revenue reflects the company’s dual-segment strategy. The biochemical division manufactures chlortetracycline (CTC) premix and CTC hydrochloride products under the Shihao and Citifac brands. These feed additives promote livestock growth and disease prevention. The industrial segment provides caterpillar machinery sales, leasing, and servicing, plus automotive components manufacturing. This diversification provides revenue stability across economic cycles.

Earnings Per Share

Chia Tai reported $0.1701 earnings per share, translating to strong profitability on a per-share basis. The company maintains a 9.07 price-to-earnings ratio, suggesting reasonable valuation relative to earnings power. With 240.7 million shares outstanding, the EPS figure reflects efficient capital structure management and solid bottom-line performance.

Profitability Metrics

The company’s 6.39% net profit margin indicates disciplined cost control. Operating margins reached 7.67%, showing effective operational efficiency. Return on equity stands at 11.11%, demonstrating reasonable returns for shareholders. These metrics position Chia Tai favorably within the drug manufacturing and industrial equipment sectors.

Growth Trajectory and Year-Over-Year Comparison

Chia Tai showed meaningful growth momentum in recent periods. The company’s financial growth metrics reveal expanding profitability and operational scale.

Revenue and Earnings Growth

Revenue expanded 74.4% year-over-year, significantly outpacing broader market growth. Net income surged 187.5%, demonstrating operating leverage and margin expansion. Earnings per share grew 194.8%, indicating strong per-share value creation. These growth rates substantially exceed typical pharmaceutical and industrial equipment sector averages.

Operating Efficiency Gains

Operating income jumped 248.5% year-over-year, reflecting improved operational execution. Gross profit grew 58.5%, showing better pricing power or cost management. Free cash flow surged 1,196%, indicating exceptional cash generation capability. These metrics suggest management successfully scaled operations while maintaining profitability.

Forward Growth Outlook

Analysts project $12.11 yearly revenue and $22.67 three-year revenue based on current trends. Five-year forecasts suggest $33.22 revenue, implying sustained mid-to-high single-digit annual growth. These projections assume continued market demand for feed additives and industrial equipment services.

Stock Price Reaction and Market Sentiment

The market responded negatively to earnings despite solid financial results. Stock price dynamics reveal investor concerns about valuation or forward guidance.

Post-Earnings Price Movement

Chia Tai shares declined 4.5% immediately following the May 13 announcement. The stock fell from HK$9.10 to HK$8.69, representing a HK$0.41 drop. Trading volume reached 44,300 shares, below the 164,164 average daily volume, suggesting limited institutional participation in the selloff.

Technical Indicators and Momentum

Technical analysis shows mixed signals. The RSI at 72.48 indicates overbought conditions, suggesting potential pullback risk. The MACD histogram at 0.09 shows weakening momentum. However, the Stochastic %K at 88.57 and Money Flow Index at 79.74 indicate strong buying pressure. These conflicting signals suggest profit-taking after recent gains.

Valuation Context

At HK$8.69, the stock trades at 9.07x trailing earnings and 0.59x price-to-sales. The 1.02x price-to-book ratio suggests fair valuation relative to net assets. Year-to-date performance shows 23.86% gains, with one-year returns exceeding 454%, indicating substantial prior appreciation.

Meyka AI Analysis and Investment Grade

Meyka AI assigns 3839.HK a B+ grade based on comprehensive fundamental analysis. This rating reflects balanced strengths and concerns across multiple financial dimensions.

Grade Components and Scoring

The B+ grade (score: 71.85/100) incorporates sector comparison (16%), industry benchmarking (16%), key metrics analysis (16%), financial growth (12%), forecasts (8%), analyst consensus (14%), and fundamental growth (7%). Return on assets scores 5/5 (Strong Buy), while return on equity earns 4/5 (Buy). Debt-to-equity metrics score 2/5 (Sell), reflecting moderate leverage concerns. Price-to-earnings valuation scores 3/5 (Neutral).

Financial Health Assessment

The company maintains 1.57x current ratio, indicating solid short-term liquidity. Debt-to-equity stands at 0.20, showing conservative leverage. Interest coverage reaches 36.15x, demonstrating strong debt service capability. Working capital totals $87.3 million, providing operational flexibility.

Investment Recommendation

Meyka AI’s neutral recommendation suggests balanced risk-reward. The company offers reasonable valuation, strong growth, and solid profitability. However, moderate debt levels and technical overbought conditions warrant caution. Investors should monitor quarterly results for sustained growth confirmation.

Final Thoughts

Chia Tai Enterprises delivered strong earnings with $773.34 million revenue and $0.1701 EPS, supported by impressive 74.4% revenue growth and 194.8% EPS expansion. The market’s 4.5% post-earnings decline reflects profit-taking after substantial year-to-date gains rather than earnings disappointment. Meyka AI’s B+ grade acknowledges solid fundamentals, reasonable valuation at 9.07x earnings, and strong cash generation, though moderate leverage and technical overbought conditions warrant monitoring. The company’s diversified biochemical and industrial segments provide revenue stability. Investors should track quarterly trends to confirm sustained growth momentum before accumulating positions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.